Puberty Blockers

The New England Journal of Medicine continues to besmirch its once august reputation by pushing ideology rather than medical science when discussing our nation’s most contentious social issues. This is particularly true about so-called gender-affirming care for minors experiencing gender confusion. Even as repeated medical studies undercut the ideological narrative that puberty blockers, hormones, and even surgeries are the best means of caring for dysphoric children — and as country after country severely restricted those interventions — (with the exception of an unsubstantive criticism of the Cass Review) articles in the NEJM on the question usually pretend that the pushback never happened.

Now, the editors have done it again, publishing an article by Scott Skinner-Thompson, an LGBT activist law professor from the University of Colorado, Boulder, criticizing the Supreme Court for allowing Tennessee to legally prevent such interventions in children. The pretense begins with the headline, “The Faulty Logic behind the Supreme Court’s Failure to Protect Trans Minors.” To the contrary, Tennessee and other jurisdictions that have enacted such laws have done so to protect trans minors from potentially irreversible harm, in the knowledge that most gender dysphoric minors overcome their confusion by the time they reach adulthood.

Then, Skinner-Thompson leans on clearly ideological opinions by medical associations, despite at least one of which (WPATH) having been substantively discredited:

On June 18, 2025, the U.S. Supreme Court upheld Tennessee’s ban on gender-affirming hormonal treatment for transgender minors against an Equal Protection Clause challenge in United States v. Skrmetti. Transgender adolescents who need these medical interventions but live in one of the many states that ban them may need to look elsewhere for care. Nearly every major relevant U.S. health care organization has concluded that the prescription of hormones and puberty blockers for treating gender dysphoria in transgender adolescents is often medically appropriate in that it can improve mental health and well-being, whereas untreated gender dysphoria can lead to depression, anxiety, and suicidality.

The American medical establishment remains radically committed to the misnamed “gender-affirming care” model, refusing to even consider following the examples of the U.K., Sweden, Denmark, Finland, New Zealand, France, Norway, and others whose health ministries have hit the brakes hard on providing puberty blockers, hormones, and surgeries to gender dysphoric children.

Example: The current New England Journal of Medicine published a “Perspectives” screed attacking the Cass Review — widely respected for its thorough investigation of the lack of significant data supporting puberty blocking of gender dysphoric children. From “The Future of Gender Affirming Care“:

Our concern here is that the Review transgresses medical law, policy, and practice, which puts it at odds with all mainstream U.S. expert guidelines. The report deviates from pharmaceutical regulatory standards in the United Kingdom. And if it had been published in the United States, where it has been invoked frequently, it would have violated federal law because the authors failed to adhere to legal requirements protecting the integrity of the scientific process.

The tide is really turning against the gender ideologues who advocate experimenting on the bodies of children as a supposedly “medically necessary” treatment. Now, Italy’s National Bioethics Committee has recommended substantially ending the use of puberty-blocking drugs as a “treatment” for childhood gender confusion. From the Society for Evidence Based Gender Medicine’s press release: Excellent. If the government follows the advice of its bioethics commission, Italy will join a burgeoning list of countries — which includes the U.K., France, New Zealand, Finland, Norway, Sweden, France, and Denmark actively taking steps to end the madness. Once the execrable Admiral Levine is out of office as Trump reenters the presidency, I expect the U.S. to follow suit. That will leave the American medical establishment and a short Read More ›

It is increasingly clear that there is little scientific basis for administering puberty blockers to gender-dysphoric youth. Consequently, many European countries have now effectively banned their use outside of official studies. Now, the New Zealand Ministry of Health has similarly found that there is a “dearth” of evidence supporting blocking normal adolescence in youngsters who feel that their gender is different from their sex. The New Zealand study reviewed all the literature on the question published before September 30, 2023. In other words, it was a study of the findings of published studies. First, it found that studies claiming that puberty blockers helped ease depression were of very poor quality. From “Impact of Puberty Blockers in Gender-Dysphoric Adolescents” (my emphasis): Impact of puberty blockers on Read More ›